Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00IUG
|
||||
| Former ID |
DAP000303
|
||||
| Drug Name |
Levobunolol
|
||||
| Synonyms |
Akbeta; Betagan; Levobunololum; Levobunolol HCl; Betegan (TN); Levobunolol (INN); Levobunolol [INN:BAN]; Levobunololum [INN-Latin]; Liquifilm (TN); W-6412A; W-7000A; AK-Beta (TN); (-)-Bunolol; (S)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2H-naphthalen-1-one; 5-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Open-angle glaucoma [ICD9: 365; ICD10:H40-H42] | Approved | [1], [2] | ||
| Therapeutic Class |
Sympatholytics
|
||||
| Company |
Allergan Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H25NO3
|
||||
| InChI |
InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1
|
||||
| InChIKey |
IXHBTMCLRNMKHZ-LBPRGKRZSA-N
|
||||
| CAS Number |
CAS 47141-42-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10116, 7979771, 8147013, 8176045, 11112712, 11112713, 11466875, 11467995, 11486490, 14800093, 34705356, 46507518, 47216948, 47440435, 47810938, 47810939, 49698660, 50064797, 50100511, 57312300, 75377008, 85787332, 96024805, 104331810, 117598030, 123099352, 128233843, 134223509, 134337615, 135002286, 135650031, 137004994, 141191903, 160964543, 162172878, 163418962, 163851154, 164789572, 172860923, 175268158, 179150487, 184531333, 198967741, 223554927, 224987628, 226412538, 252351251
|
||||
| ChEBI ID |
ChEBI:6438
|
||||
| SuperDrug ATC ID |
S01ED03
|
||||
| SuperDrug CAS ID |
cas=047141424
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Endocytosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Gap junction | |||||
| Salivary secretion | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Beta1 adrenergic receptor signaling pathway | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Adrenoceptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 570). | ||||
| REF 3 | Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.